BioSpace News Archive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to announce that data from its AIPAC, TACTI-002 and TACTI-003 studies have been published in abstracts available via the links below on the SITC 2021 Annual Meeting’s official website or the Company’s website.

Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic stem cell therapeutics, today announced that it has entered into a non-exclusive research collaboration with AVROBIO, Inc. to evaluate the use of JSP191.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced the first clinical data from its Agonist Redirected Checkpoint (ARC) platform compounds, SL-172154 and SL-279252.

A new imaging technique, developed by the teams of Professors Jinyang Liang and Fiorenzo Vetrone at the Institut national de la recherche scientifique, can measure temperature in 2D, without contact, and in just a snap.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today reported financial results for the third quarter ended September 30, 2021.

As assay developers and clinical testing laboratories consider next steps for molecular diagnostics post-pandemic, a new in vitro diagnostic (IVD) system from Thermo Fisher Scientific will enable them to expand their assay menus and IVD testing capabilities moving forward.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced a poster presentation with new preclinical data for CI-8993, a first-in-class monoclonal antibody VISTA antagonist, at the Society for Immunotherapy of Cancer’s 36th Annual Meeting.

Sirona Medical, a software company founded on a deep understanding of both the practice and business of radiology, today announced $40 million in Series B financing, bringing the total capital raised to more than $60 million.

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, announced the appointments of Miriam Merad, MD, PhD, and David G. DeNardo, PhD, to the company’s scientific advisory board.

I-Mab (Nasdaq: IMAB), and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a clinical-stage biotech developing bispecific antibody technology for immune-oncology and neurodegenerative diseases, today jointly announced preclinical data of their 4-1BB bispecific antibodies at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting.